Charles A. Rowland Jr - Oct 27, 2025 Form 4 Insider Report for Viking Therapeutics, Inc. (VKTX)

Role
Director
Signature
/s/ Michael Morneau, as Attorney-in-Fact
Stock symbol
VKTX
Transactions as of
Oct 27, 2025
Transactions value $
-$1,827,638
Form type
4
Date filed
10/28/2025, 07:49 PM
Previous filing
Jun 6, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Rowland Charles A Jr Director C/O VIKING THERAPEUTICS, INC., 9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO /s/ Michael Morneau, as Attorney-in-Fact 2025-10-28 0001383292

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VKTX Common Stock, par value $0.00001 per share Award $71.7K +16K +53.33% $4.48 46K Oct 27, 2025 Direct
transaction VKTX Common Stock, par value $0.00001 per share Award $128K +22K +47.83% $5.80 68K Oct 27, 2025 Direct
transaction VKTX Common Stock, par value $0.00001 per share Award $107K +22K +32.35% $4.88 90K Oct 27, 2025 Direct
transaction VKTX Common Stock, par value $0.00001 per share Sale -$2.13M -60K -66.67% $35.57 30K Oct 27, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VKTX Stock Option (Right to Buy) Options Exercise $0 -16K -100% $0.00 0 Oct 27, 2025 Common Stock 16K $4.48 Direct
transaction VKTX Stock Option (Right to Buy) Options Exercise $0 -22K -100% $0.00 0 Oct 27, 2025 Common Stock 22K $5.80 Direct
transaction VKTX Stock Option (Right to Buy) Options Exercise $0 -22K -100% $0.00 0 Oct 27, 2025 Common Stock 22K $4.88 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.02 to $35.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.